Patents by Inventor Christopher CUTIE

Christopher CUTIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260144809
    Abstract: The present disclosure relates generally to methods of treating high-risk non-muscle invasive bladder cancer (HR-NMIBC), and more specifically to methods of treating Bacillus Calmette-Guérin (BCG)-naïve HR-NMIBC in individuals by administering intravesical gemcitabine.
    Type: Application
    Filed: September 12, 2025
    Publication date: May 28, 2026
    Inventors: Christopher CUTIE, Kiran PATEL, Hussein SWEITI
  • Patent number: 12636300
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: May 26, 2026
    Assignee: Janssen Biotech, Inc.
    Inventors: Dennis Giesing, Christopher Cutie
  • Patent number: 12029749
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: July 9, 2024
    Assignee: TARIS BIOMEDICAL LLC
    Inventors: Dennis Giesing, Christopher Cutie
  • Publication number: 20230321129
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 12, 2023
    Inventors: Dennis GIESING, Christopher CUTIE
  • Publication number: 20210085705
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Inventors: Dennis Giesing, Christopher Cutie
  • Patent number: 10792297
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: October 6, 2020
    Assignee: TARIS Biomedical LLC
    Inventors: Dennis Giesing, Christopher Cutie
  • Publication number: 20190388338
    Abstract: The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.
    Type: Application
    Filed: May 5, 2017
    Publication date: December 26, 2019
    Applicant: Taris Biomedical LLC
    Inventors: Dennis GIESING, Christopher CUTIE, Purnanand SARMA, Cheryl LARRIVEE-ELKINS, Christopher SEARCY, Vikas AGARWAL
  • Publication number: 20190175637
    Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
    Type: Application
    Filed: November 7, 2018
    Publication date: June 13, 2019
    Applicant: Taris Biomedical LLC
    Inventors: Dennis GIESING, Christopher CUTIE